From Casetext: Smarter Legal Research

In re Xyrem (Sodium Oxybate) Antitrust Litig.

United States District Court, Northern District of California
Aug 3, 2023
3:20-md-02966-RS (N.D. Cal. Aug. 3, 2023)

Opinion

3:20-md-02966-RS

08-03-2023

IN RE XYREM (SODIUM OXYBATE) ANTITRUST LITIGATION

Jeffrey Faucette SKAGGS FAUCETTE LLP Heidi K. Hubbard (pro hac vice) Stanley E. Fisher (pro hac vice) Benjamin M. Greenblum (pro hac vice) WILLIAMS & CONNOLLY LLP Attorneys for Defendants Jazz Pharmaceuticals, Inc., Jazz Pharmaceuticals Ireland Limited, and Jazz Pharmaceuticals Public Limited Company Dena C. Sharp Scott Grzenczyk Tom Watts Jordan Isern GIRARD SHARP LLP Michael M. Buchman (pro hac vice) Jacob Onile-Ere (pro hac vice) MOTLEY RICE LLC Co-Lead Class Counsel Jack E. Pace III (pro hac vice) WHITE & CASE LLP Kathryn J. Mims (pro hac vice) WHITE & CASE LLP WHITE & CASE LLP 3000 El Camino Real Attorneys for Defendants Hikma Pharmaceuticals PLC, Eurohealth (U.S.A.), Inc., West-Ward Pharmaceuticals Corp. n/k/a Hikma Pharmaceuticals USA Inc., and Roxane Laboratories, Inc. n/k/a Hikma Labs Inc. Devora W. Allon, P.C. (pro hac vice) Jay P. Lefkowitz, P.C. (pro hac vice) KIRKLAND & ELLIS LLP Attorneys for Defendants Lupin Pharmaceuticals Inc., Lupin Inc., and Lupin Ltd. Matthew H. Ladner (SBN 284594) TROUTMAN PEPPER HAMILTON SANDERS LLP Robin P. Sumner (pro hac vice) Melissa Hatch O'Donnell (pro hac vice) TROUTMAN PEPPER HAMILTON SANDERS LLP Attorneys for Defendant Amneal Pharmaceuticals LLC


Jeffrey Faucette SKAGGS FAUCETTE LLP

Heidi K. Hubbard (pro hac vice) Stanley E. Fisher (pro hac vice) Benjamin M. Greenblum (pro hac vice) WILLIAMS & CONNOLLY LLP

Attorneys for Defendants Jazz Pharmaceuticals, Inc., Jazz Pharmaceuticals Ireland Limited, and Jazz Pharmaceuticals Public Limited Company

Dena C. Sharp Scott Grzenczyk Tom Watts Jordan Isern GIRARD SHARP LLP

Michael M. Buchman (pro hac vice) Jacob Onile-Ere (pro hac vice) MOTLEY RICE LLC

Co-Lead Class Counsel

Jack E. Pace III (pro hac vice) WHITE & CASE LLP

Kathryn J. Mims (pro hac vice) WHITE & CASE LLP

WHITE & CASE LLP 3000 El Camino Real

Attorneys for Defendants Hikma Pharmaceuticals PLC, Eurohealth (U.S.A.), Inc., West-Ward Pharmaceuticals Corp. n/k/a Hikma Pharmaceuticals USA Inc., and Roxane Laboratories, Inc. n/k/a Hikma Labs Inc.

Devora W. Allon, P.C. (pro hac vice) Jay P. Lefkowitz, P.C. (pro hac vice) KIRKLAND & ELLIS LLP

Attorneys for Defendants Lupin Pharmaceuticals Inc., Lupin Inc., and Lupin Ltd.

Matthew H. Ladner (SBN 284594) TROUTMAN PEPPER HAMILTON SANDERS LLP

Robin P. Sumner (pro hac vice) Melissa Hatch O'Donnell (pro hac vice) TROUTMAN PEPPER HAMILTON SANDERS LLP

Attorneys for Defendant Amneal Pharmaceuticals LLC

JOINT STIPULATION AND ORDER TO CHANGE THE DATE OF THE AUGUST 10, 2023 CASE MANAGEMENT CONFERENCE

HON. RICHARD SEEBORG, UNITED STATES CHIEF DISTRICT JUDGE

Pursuant to Civil Local Rules 6-2 and 7-12, Plaintiffs in the Consolidated Class Actions (“Class Plaintiffs”), Plaintiff United Healthcare Services, Inc. (“UHS”), Plaintiffs Humana Inc., Molina Healthcare, Inc., and Health Care Service Corporation, Inc. (with Class Plaintiffs, the “Plaintiffs”), and and Defendants Jazz Pharmaceuticals, Inc., Jazz Pharmaceuticals Ireland Limited, and Jazz Pharmaceuticals Public Limited Company, Hikma Pharmaceuticals USA, Inc. (f/k/a WestWard Pharmaceuticals Corp.), Hikma Labs Inc. (f/k/a Roxane Laboratories, Inc.), Amneal Pharmaceuticals LLC, Lupin Pharmaceuticals, Inc., and Lupin, Inc. (“Defendants”) (with Plaintiffs, the “Parties”) hereby stipulate and ask the Court to adjust the date of the next Case Management Conference in the above-referenced matter, currently set for Thursday, August 10, 2023, at 10:00 a.m., to August 17, 2023, at 10:00 a.m.:

WHEREAS, the Case Management Conference is currently set for August 10, 2023, at 10:00 a.m., but class counsel has a conflict at that time;

WHEREAS, the Parties have conferred and agree, subject to this Court's approval, to reschedule the Case Managemnt Conference to August 17, 2023;

WHEREAS, the Parties will submit their case management statement, as planned, on August 3, 2023;

WHEREAS, the proposed change of date will not alter the date of any event or any deadline already fixed by Court order;

NOW THEREFORE, the Parties, through their undersigned counsel, hereby stipulate and respectfully request that the Court enter an Order rescheduling the next Case Management Conference to August 17, 2023, at 10 a.m.

ATTESTATION PURSUANT TO CIVIL LOCAL RULE 5-1(i)(3)

I, Dena C. Sharp, am the ECF user whose identification and password are being used to file this document. In compliance with Local Rule 5-1(i)(3), I hereby attest that all signatories hereto concur in this filing.

ORDER

IT IS SO ORDERED.


Summaries of

In re Xyrem (Sodium Oxybate) Antitrust Litig.

United States District Court, Northern District of California
Aug 3, 2023
3:20-md-02966-RS (N.D. Cal. Aug. 3, 2023)
Case details for

In re Xyrem (Sodium Oxybate) Antitrust Litig.

Case Details

Full title:IN RE XYREM (SODIUM OXYBATE) ANTITRUST LITIGATION

Court:United States District Court, Northern District of California

Date published: Aug 3, 2023

Citations

3:20-md-02966-RS (N.D. Cal. Aug. 3, 2023)